Association Between Airway Parameters and Abdominal Fat Measured via Computed Tomography in Asthmatic Patients

Min Suk Yang,1 Sanghun Choi,2 Yera Choi,3 Kwang Nam Jin 3*

1Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
2Department of Mechanical Engineering, Kyungpook National University, Daegu, Korea
3Department of Radiology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

ABSTRACT

Purpose: We aimed to investigate whether airway parameters, assessed via computed tomography (CT), are associated with abdominal fat areas and to compare the clinical characteristics of asthmatic patients with and without elevated visceral to subcutaneous fat area ratio (EV).

Methods: Asthmatic patients (aged ≥40 years) were prospectively recruited. Chest (airway) and fat areas were assessed via CT. Airway parameters, including bronchial wall thickness (WT), lumen diameter (LD), lumen area (LA), wall area (WA), total area (TA), as well as WA/TA percentage (wall area %) were measured at the apical segmental bronchus in the right upper lobe. Visceral (VFA), subcutaneous (SFA) and total (TFA) fat areas (cm^2) were also measured. The correlations between abdominal fat areas and airway parameters were assessed. EV was defined as VFA/SFA ≥ 0.4.

Results: Fifty asthmatic patients were included (mean age 62.9 years; 52% female); 38% had severe asthma. Significant correlations were found between VFA and both LD and LA (r = −0.35, P = 0.01; r = −0.34, P = 0.02, respectively), and SFA and both WA and TA (r = 0.38, P = 0.007; r = 0.34, P = 0.02, respectively). Exacerbations, requiring corticosteroid therapy or ER visitation, were significantly more frequent in subjects without EV (83% vs. 34%, P = 0.05).

Conclusions: Abdominal fat is associated with asthma, according to the location of fat accumulation. In asthmatic subjects, visceral fat seems to be attributable to the bronchial luminal narrowing, while subcutaneous fat may be related to thickening of bronchial wall.

Keywords: Asthma; abdominal fat; multidetector computed tomography

INTRODUCTION

Obesity is associated with a higher incidence and prevalence of asthma.1,3 Moreover, obesity increases asthma severity and impairs patients’ response to management.4-6 High body mass index (BMI) or waist circumference have been established as risk factors for asthma in adults.5,6 Abdominal obesity may be related to asthma via multifactorial mechanisms including mechanical alterations in the airways and lung parenchyma, systemic and airway inflammation and metabolic dysregulation, adversely influencing lung function and/or...
response to therapy. Adipokines such as leptin and adiponectin were proposed to affect airway inflammation of asthma through their systemic effects. However, human studies on the adipokines and asthma did not show consistent results. In addition, although research on the effect of weight reduction in severe asthmatics mostly reported improved asthma control and airway parameters which could be improved by reduction in both mechanical alteration and systemic inflammation, its effects on airway inflammation and airway hyperresponsiveness were not obvious in some studies. This raised the possibility that some characteristics of adipose tissues such as distribution within human body would influence the way adipose tissue affect asthma. With recent advances in multi-detector computed tomography (CT), imaging-based quantification of abdominal fat allows the separate measurement of subcutaneous and visceral fat area, providing visceral to subcutaneous fat area ratio (V/S). The fat distribution analysis has been widely performed to show the association of obesity with metabolic syndrome or cardiovascular diseases. Moreover, CT enables the exact measurement of airway and pulmonary parenchyma such as bronchial lumen diameter (LD) or wall thickness (WT), emphysema and air-trapping in asthmatic patients. However, to our knowledge, no studies have yet performed simultaneous CT assessment of the airways, lung parenchyma and abdominal fat area to demonstrate the association between asthma and obesity.

In this study, we aimed to investigate whether airway parameters, emphysema or air trapping are associated with abdominal fat areas or certain types of adipose tissue, measured via CT or BMI, and to compare the clinical characteristics of asthmatic patients with and without elevated V/S (EV).

**MATERIALS AND METHODS**

**Study population**

From December 2014 to August 2016, patients of all weight status diagnosed with asthma, aged ≥40 years, who visited the outpatient asthma clinic at our hospital, were prospectively enrolled in the study. Asthma was diagnosed when a patient had more than 1 asthma symptom, including dyspnea, wheezing, chest tightness, and/or cough, and objective evidence of variable airway obstruction and/or hyper-responsiveness. Variable airway obstruction was defined as a 12% (200 mL from baseline) increase in forced expiratory volume in 1 second (FEV1) after bronchodilator use or 4-weeks of treatment with anti-inflammatory agents. Airway hyper-responsiveness was tested by the methacholine bronchial provocation test, using standard methods. Patients who refused to participate in this study, had any other pulmonary diseases, and/or whose CT datasets contained any post-processing failure were excluded.

**Clinical characteristics**

We explored patients' clinical characteristics including age, sex, height, weight, BMI, body surface area (BSA), smoking status, presence of atopy and chronic rhinitis, age at asthma diagnosis, asthma duration, number of exacerbations (requiring the use inhaled or systemic corticosteroid agents or emergency department visits) within the previous year, and Quality of Life Questionnaire for Adult Korean Asthmatics (QLQAKA) score (range 1 to 5 [minimal clinically important difference 0.5]; higher scores representing better quality of life). Atopy was identified following 1 or more positive results to common inhalant allergens via skin or serum specific immunoglobulin E (IgE) tests. Chronic rhinitis was confirmed if
rhinorrhea with 1 or more symptoms including itching, sneezing and nasal obstruction was present chronically. Severe asthma was defined as per the European Respiratory Society (ERS)/American Thoracic Society (ATS) guideline, as either: 1) asthma “controlled” with high-dose inhaled corticosteroids and a second agent (i.e., systemic corticosteroids); or 2) “uncontrolled” asthma despite high-dose inhaled corticosteroids and a second agent (i.e., systemic corticosteroids). Asthma exacerbation was defined as: 1) worsening of asthma requiring systemic corticosteroids; 2) an increase from a stable maintenance corticosteroid dose for at least 3 days; or 3) emergency department visitation or hospitalization due to asthma requiring systemic corticosteroids.

Baseline and post-bronchodilator FEV1, forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow between 25%–75% (FEF25–75) were recorded in all patients. The percentages of predicted FVC and FEV1 values were calculated.

**CT image acquisition and quantification of airway and fat areas**

To assess airway and fat areas CT scans were performed on all patients using a 128-multi-detector computed tomography scanner (Ingenuity CT; Philips Healthcare, Cleveland, OH, USA). The protocol for acquiring chest (airway) CT scans was as follows: detector collimation, 64 × 0.625 mm; rotation speed, 0.42 seconds; pitch, 1.25; tube voltage, 120 kV; tube current, 50 mAs; and automatic tube current modulation technique. Both inspiration and expiration chest (airway) CT images were obtained with slice thicknesses and intervals of 0.625 mm, using a standard algorithm (without an iterative reconstruction algorithm). The protocol for acquiring fat CT scans was as follows: level of the umbilicus; tube voltage, 140 kV; and tube current, 33 mAs. Axial fat CT images were reconstructed with slice thicknesses and intervals of 5.0 mm, using a standard algorithm. Transverse datasets were transferred to dedicated workstations to quantify airway and fat areas.

Airway parameters, including bronchial WT, LD, lumen area (LA), wall area (WA), total area (TA) and WA/TA percentage (wall area %), were semi-automatically measured at the apical segmental bronchus of the right upper lobe, which has been used as the target anatomic location to assess airway remodeling in asthmatic patients, by a single radiologist. The predicted diameter and WT of the trachea were calculated using age, sex and height (as references to normalize the corresponding airway parameters). Emphysema and air-trapping scores were automatically calculated with low attenuation areas, below −950 and −856 HU in inspiration and expiration CT images, respectively.

Visceral (VFA), subcutaneous (SFA) and total (TFA) fat areas (cm²) were automatically measured and recorded. The fat areas used in the current study were indexed to BSA to account for variations in lean body mass and overall body size. A V/S of ≥ 0.4 was defined as EV. The correlation between abdominal fat areas, including VFA, SFA, and TFA, and airway parameters, emphysema % and air-trapping %, were assessed. The clinical characteristics of patients with and without EV were compared.

**Statistical analysis**

The sample size was calculated to power the study to test the correlation coefficient. With the assumption that the expected correlation coefficient would be 0.390 based on the result of previous study showing the correlation between airway WT and BMI, we determined that 49 subjects are required for statistical power of 0.80 to prove the hypothesis with two-sided test at a 0.05 significance level. All data are expressed as means ± standard deviations.

https://doi.org/10.4168/aair.2018.10.5.503
Correlation analyses were performed using coefficients. Dichotomous variables were compared using $\chi^2$ tests, and continuous variables were compared using Student’s $t$ tests for normally distributed variables and Wilcoxon rank-sum tests for non-normally distributed variables. Multiple linear regression or logistic regression were performed to control the effect of age. P values < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS 20.0 (IBM SPSS Statistics; IBM Corp., Armonk, NY, USA).

**Ethics**

This prospective study was approved by the Institutional Review Board of SMG-SNU Boramae Medical Center (Seoul, Korea, IRB No. 16-2014-103). All clinical investigations were conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

**RESULTS**

**Clinical characteristics and CT variables**

A total of 54 patients participated in this study; however, 4 were excluded because they refused to undergo CT scanning due to claustrophobia ($n = 1$), consent withdrawal ($n = 1$), primary lung cancer ($n = 1$) and CT post-processing failure ($n = 1$). Thus, 50 patients were included in the analysis (mean age ± SD, 62.9 ± 10.6 years; 26/50 [52%] female).

Obesity with BMI ≥ 25 was found in 27 subjects (54%). Six (12%) subjects were current smokers, and 7 (14%) had atopy. Thirty (60%) subjects complained of chronic rhinitis symptoms, and 19 (38%) had severe asthma. The mean pre-bronchodilator FEV1 was 2.16 ± 0.64 L, and the mean post-bronchial FEV1 was 2.24 ± 0.62 L. Table 1 shows patients’ clinical characteristics and pulmonary function test results. Table 2 shows patients’ airway parameters including bronchial LD, WT, LA, WA, TA, wall area % (Fig. 1), emphysema %, air-trapping % and abdominal fat areas including VFA, SFA, and TFA (Fig. 2).

Correlation analyses (between abdominal fat areas and airway parameters, emphysema %, and air-trapping %) revealed significant negative correlations between VFA and both bronchial LD and LA ($r = -0.35$, $P = 0.01$; $r = -0.34$, $P = 0.01$, respectively; Table 3) and significant positive correlations between SFA and both bronchial WA and TA ($r = 0.38$, $P = 0.007$; $r = 0.34$, $P = 0.01$, respectively; Fig. 3); no significant correlations were found for TFA. Emphysema and air-trapping % did not correlate significantly with abdominal fat area. BMI showed significant correlations with LD and LA ($r = -0.34$, $P = 0.02$ for both; Table 3).

EV was found in 44 patients (92%). Subjects with EV were older (65 vs. 48 years, $P < 0.001$) and were diagnosed with asthma at an older age (43 vs. 56 years old, $P = 0.04$; Table 4). There were no differences in atopy, chronic rhinitis, QLQAKA score or presence of severe asthma between patients without and with EV; however, exacerbations requiring corticosteroid therapy or ER visitation were significantly more frequent in subjects without EV (83% vs. 34%, $P = 0.05$). The pulmonary function test results revealed significantly lower baseline FEV1 and post-bronchodilator FEV1% predicted in patients with EV (2.6 vs. 2.1, $P = 0.04$; 107.5 vs. 95.3, $P = 0.05$; respectively).
Table 1. Clinical characteristics and pulmonary function test results in patients with asthma

| Variables                        | Value (n = 50) |
|----------------------------------|----------------|
| Age (yr)                         | 63 ± 11 (40–81) |
| Female                           | 26 (52) |
| BMI (kg/m²)                      | 26.4 ± 3.9 (19.9–34.3) |
| BSA (m²)                         | 1.72 ± 0.18 (1.39–2.12) |
| Obesity (BMI ≥25)                | 27 (54) |
| Current smoker                   | 6 (12) |
| Atopy                            | 7 (14) |
| Chronic rhinitis                 | 30 (60) |
| Age at asthma diagnosis (yr)     | 55 ± 15 (1–79) |
| Asthma duration (yr)             | 8 ± 11 (0–45) |
| Exacerbation requiring use of corticosteroids or ER visitation | 20 (40) |
| Inhaled corticosteroid           | 48 (96) |
| Low dose                         | 8 (16) |
| Medium dose                      | 35 (70) |
| High dose                        | 5 (10) |
| QLQAKA average score             | 4 ± 1 (2–5) |
| Severe asthma                    | 19 (38) |

Baseline lung function

| FEV1 (L)                         | 2.2 ± 0.6 (1.0–3.5) |
| FEV1% predicted                  | 94 ± 21 (46–137) |
| FVC (L)                          | 3.1 ± 0.9 (1.5–5.2) |
| FVC% predicted                   | 96 ± 16 (58–123) |
| FEV1/FVC ratio (>100)            | 69 ± 9 (47–87) |
| FEF25–75 (L)                     | 1.5 ± 0.8 (0.3–4.2) |

Post-bronchodilator

| FEV1 (L)                         | 2.2 ± 0.6 (1.1–3.6) |
| FEV1% predicted                  | 97 ± 19 (54–142) |
| FVC (L)                          | 3.2 ± 0.8 (1.5–5.3) |
| FVC% predicted                   | 96 ± 16 (58–123) |
| FEV1/FVC ratio (>100)            | 71 ± 9 (49–89) |
| FEF25–75 (L)                     | 1.7 ± 0.9 (0.4–4.6) |

Values are means±SD (minimum–maximum) or number (%).

BMI, body mass index; BSA, body surface area; ER, emergency room (department); QLQAKA, Quality of Life Questionnaire for Adult Korean Asthmatics; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF, forced expiratory flow; SD, standard deviation.

Table 2. Airway parameters, emphysema, air-trapping and abdominal fat areas assessed by chest and fat area CT in 50 patients with asthma

| Variables                        | Value |
|----------------------------------|-------|
| Bronchial LD (mm)                | 0.23 ± 0.05 (0.15–0.35) |
| Bronchial WT (mm)                | 0.43 ± 0.11 (0–0.70) |
| Bronchial LA (mm³)               | 0.05 ± 0.02 (0.02–0.10) |
| Bronchial WA (mm²)               | 0.07 ± 0.03 (0–0.17) |
| Bronchial TA (mm²)               | 0.11 ± 0.04 (0.05–0.27) |
| Bronchial WA %                   | 58 ± 11 (0–77) |
| Total lung volume (L)            | 4.1 ± 1.1 (2.1–7.0) |
| Emphysema %                      | 4 ± 12 (0–61) |
| Air-trapping %                   | 17 ± 16 (0–62) |
| VFA (cm³)                        | 79 ± 33 (25–173) |
| SFA (cm³)                        | 114 ± 45 (32–231) |
| TFA (cm³)                        | 194 ± 61 (57–362) |

Data are means±SD (minimum–maximum). Airway parameters were measured at the orifice of the apical segmental bronchus in the right upper lobe and were normalized with predicted trachea diameter; and WT values calculated using age, sex, and height. The fat areas were indexed to BSA to account for variations in lean body mass and overall body size. CT, computed tomography; LD, lumen diameter; WT, wall thickness; LA, lumen area; WA, wall area; TA, total area; VFA, visceral fat area; SFA, subcutaneous fat area; TFA, total fat area; SD, standard deviation.
DISCUSSION

In this study, bronchial LD and LA, assessed via CT, were found to decrease as VFA increased in asthmatic patients. Moreover, asthmatic patients with EV had lower bronchial LDs and TAs than those without. Subcutaneous fat area is positively associated with bronchial WA, which might be a marker for airway remodeling in asthma.29

We found that different locations of adipose tissues within the body of asthmatics might be related to different airway parameters. Abdominal VFA was negatively associated with LD and LA. In addition, asthmatics with EV had smaller airway LDs and thinner airway WTs than those without. This finding is in-line with the known effect of body weight on airway caliber.30-32 A possible explanation supporting the inverse correlation between visceral fat and bronchial LD or LA is that excessive adipose tissue, accumulating around intra-abdominal organs, might push the diaphragm upward, resulting in insufficient inflation of the lungs and airway.12 Significantly lower post-bronchodilator FEV1% predicted and FVC% predicted
values in asthmatic patients with EV might also indicate that VFA was indirectly associated with the bronchial lumen. On the other hand, abdominal SFA, but not VFA, was associated with bronchial WA and TA in this study (r = 0.38, P = 0.007, r = 0.34, P = 0.01, respectively).

This is consistent with the result of a recent study exploring abdominal fat areas via CT, which revealed that subcutaneous, but not visceral, adiposity was associated with asthma. Another study demonstrating that subcutaneous abdominal fat was associated with airway hyper-responsiveness is also quite similar to our results. It was proposed that leptin which is one of the best-known systemically secreted adipokines would affect proliferation and survival of eosinophils and promote airway inflammation in several reports. Considering that there were reports describing airway inflammation in asthma could be demonstrated as bronchial wall thickening on CT, the positive association of SFA with WA or TA shown in this study might suggest that subcutaneous fat tissue may influence the airway inflammation

**Table 3. Correlation between abdominal fat s or BMI and airway parameters, emphysema %, and air-trapping % in 50 patients with asthma**

| Variables | Correlation coefficient (r) | P value |
|-----------|-----------------------------|---------|
| VFA       |                             |         |
| Bronchial LD | -0.35                      | 0.01    |
| Bronchial WT | 0.08                       | 0.58    |
| Bronchial LA | -0.34                      | 0.01    |
| Bronchial WA | -0.07                      | 0.25    |
| Bronchial TA | -0.26                      | 0.07    |
| Bronchial WA % | 0.26                      | 0.07    |
| Emphysema % | -0.03                      | 0.83    |
| Air-trapping % | -0.17                      | 0.26    |
| SFA       |                             |         |
| Bronchial LD | 0.25                       | 0.08    |
| Bronchial WT | 0.26                       | 0.07    |
| Bronchial LA | 0.23                       | 0.10    |
| Bronchial WA | 0.38                       | 0.007   |
| Bronchial TA | 0.34                       | 0.01    |
| Bronchial WA % | 0.09                      | 0.51    |
| Emphysema % | 0.02                       | 0.89    |
| Air-trapping % | -0.003                     | 0.99    |
| TFA       |                             |         |
| Bronchial LD | -0.008                     | 0.95    |
| Bronchial WT | 0.24                       | 0.10    |
| Bronchial LA | -0.02                      | 0.91    |
| Bronchial WA | 0.19                       | 0.19    |
| Bronchial TA | 0.17                       | 0.45    |
| Bronchial WA % | 0.21                      | 0.14    |
| Emphysema % | 0.001                      | 0.10    |
| Air-trapping % | -0.09                      | 0.55    |
| V/S       |                             |         |
| Bronchial LD | -0.44                      | 0.001   |
| Bronchial WT | -0.132                     | 0.361   |
| Bronchial LA | -0.421                     | 0.002   |
| Bronchial WA | -0.409                     | 0.003   |
| Bronchial TA | -0.450                     | 0.001   |
| Bronchial WA % | 0.091                      | 0.528   |
| Emphysema % | -0.064                     | 0.673   |
| Air-trapping % | -0.183                     | 0.229   |
| BMI       |                             |         |
| Bronchial LD | -0.34                      | 0.02    |
| Bronchial WT | 0.01                       | 0.94    |
| Bronchial LA | -0.34                      | 0.02    |
| Bronchial WA | -0.18                      | 0.21    |
| Bronchial TA | -0.27                      | 0.06    |
| Bronchial WA % | 0.19                      | 0.19    |
| Emphysema % | -0.10                      | 0.53    |
| Air-trapping % | -0.12                      | 0.42    |

Correlation analyses were performed using Pearson's correlation coefficients.

BMI, body mass index; VFA, visceral fat area; SFA, subcutaneous fat area; TFA, total fat area; V/S, visceral to subcutaneous fat area ratio; LD, lumen diameter; WT, wall thickness; LA, lumen area; WA, wall area; TA, total area.
through systemically secreted adipokines. These results were unexpected because visceral fat was better known to be more related to systemic inflammation than subcutaneous fat in other diseases. Visceral adiposity was proposed to be associated with type 2 diabetes, inflammation, dyslipidemia and non-alcoholic fatty liver disease (NAFLD), whereas subcutaneous adiposity was not. There were several factors that distinguish visceral and subcutaneous adiposity. 

Fig. 3. Scatter diagrams and line of best fit showing correlation between VFA (A) or SFA (B) and airway parameters including bronchial LD, bronchial WT, bronchial LA, bronchial WA, bronchial TA and bronchial WA %. VFA, visceral fat area; SFA, subcutaneous fat area; LD, lumen diameter; WT, wall thickness; LA, lumen area; WA, wall area; TA, total area.

https://e-aair.org

https://doi.org/10.4168/aair.2018.10.5.503
subcutaneous fat tissues, including adipokines and cytokine production, and lipid storage and mobilization abilities. Regarding NAFLD, visceral fat is anatomically linked to the liver through the portal vein. The ability of visceral adipose tissue to deliver free fatty acids and adipokines/cytokines to the liver is likely to explain the association between visceral fat and NAFLD. However, our results suggest that subcutaneous adiposity may be related to airway inflammation more than visceral adiposity unlike in other diseases.

Table 4. Comparison of the clinical characteristics and CT variables between asthmatic patients without and with EV measured on CT

| Variables                                      | No EV (n = 6) | EV (n = 44) | P value | P value* |
|------------------------------------------------|--------------|-------------|---------|----------|
| Age (yr)                                       | 47.8 ± 5.6   | 65 ± 9.4    | < 0.001 | < 0.001  |
| Sex (female)                                   | 6 (100)      | 20 (46)     | 0.02    |          |
| BMI (kg/m²)                                    | 26.5 ± 4.2   | 26.5 ± 4.0  | 0.97    | 0.85     |
| BSA (m²)                                       | 1.7 ± 0.1    | 1.7 ± 0.2   | 0.98    | 0.43     |
| Current smoker                                 | 0            | 6 (14)      | 0.34    | 0.99     |
| Atopy                                          | 2 (33)       | 5 (11)      | 0.15    | 0.96     |
| Chronic rhinitis                               | 5 (83)       | 25 (57)     | 0.21    | 0.45     |
| Age at asthma diagnosis (yr)                   | 43 ± 7       | 56 ± 15     | 0.04    | 0.65     |
| Asthma duration (yr)                           | 5 ± 5        | 9 ± 12      | 0.43    | 0.65     |
| Asthma exacerbation requiring use of corticosteroid or ER visitation | 5 (83) | 14 (34) | 0.03 | 0.05 |
| QLQAKA score                                   | 3 ± 1        | 4 ± 1       | 0.14    | 0.49     |
| Severe asthma                                  | 1 (17)       | 18 (41)     | 0.39    | 0.15     |
| Baseline lung function                         |              |             |         |          |
| FEV1 (L)                                       | 2.6 ± 0.4    | 2.1 ± 0.6   | 0.08    | 0.04     |
| FEV1% predicted                                | 103 ± 11     | 93 ± 22     | 0.26    | 0.09     |
| FVC (L)                                        | 3.5 ± 0.6    | 3.1 ± 0.9   | 0.19    | 0.59     |
| FVC% predicted                                 | 108 ± 8      | 95 ± 16     | 0.06    | 0.11     |
| FEV1/FVC ratio (~100)                          | 73 ± 6       | 69 ± 9      | 0.29    | 0.18     |
| FEF25–75 (L)                                   | 2.0 ± 0.6    | 1.5 ± 0.8   | 0.16    | 0.69     |
| Post-bronchodilator lung function              |              |             |         |          |
| FEV1 (L)                                       | 2.7 ± 0.3    | 2.2 ± 0.6   | 0.06    | 0.85     |
| FEV1% predicted                                | 108 ± 6      | 95 ± 20     | 0.006   | 0.05     |
| FVC (L)                                        | 3.6 ± 0.5    | 3.1 ± 0.9   | 0.20    | 0.47     |
| FVC% predicted                                 | 108 ± 7      | 95 ± 15     | 0.04    | 0.12     |
| FEV1/FVC ratio (~100)                          | 76 ± 5       | 70 ± 9      | 0.16    | 0.08     |
| FEF25–75 (L)                                   | 2.2 ± 0.4    | 1.6 ± 0.9   | 0.08    | 0.28     |
| Viscera to subcutaneous fat ratio              | 0.3 ± 0.0    | 0.8 ± 0.4   | < 0.001 | 0.004   |
| Visceral fat area (cm²)                        | 48 ± 14      | 84 ± 33     | 0.01    | 0.08     |
| Subcutaneous fat area (cm²)                    | 161 ± 45     | 108 ± 42    | 0.006   | 0.005    |
| Total fat area (cm²)                           | 209 ± 58     | 192 ± 62    | 0.52    | 0.28     |
| Bronchial LD (mm)                              | 0.28 ± 0.05  | 0.23 ± 0.05 | 0.02    | 0.08     |
| Bronchial WT (mm)                              | 0.47 ± 0.12  | 0.44 ± 0.09 | 0.46    | 0.26     |
| Bronchial LA (mm)                              | 0.06 ± 0.02  | 0.04 ± 0.02 | 0.01    | 0.05     |
| Bronchial WA (mm)                              | 0.08 ± 0.04  | 0.06 ± 0.02 | 0.07    | 0.07     |
| Bronchial wall TA (mm)                         | 0.15 ± 0.07  | 0.11 ± 0.03 | 0.02    | 0.04     |
| Bronchial WA %                                 | 57 ± 5       | 60 ± 8      | 0.27    | 0.78     |
| Total lung volume (L)                          | 4.0 ± 0.8    | 4.2 ± 1.2   | 0.67    | 0.18     |
| Emphysema (%)                                  | 0.2 ± 0.4    | 4.2 ± 12.6  | 0.45    | 0.56     |
| Air-trapping (%)                               | 12 ± 9       | 18 ± 17     | 0.45    | 0.52     |

Data are mean±SD or number (%). EV was defined as VFA/SFA ≥0.4.
CT, computed tomography; EV, elevated visceral to subcutaneous fat area ratio; BMI, body mass index; BSA, body surface area; ER, emergency room (department); QLQAKA, Quality of Life Questionnaire for Adult Korean Asthmatics; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF, forced expiratory flow; LD, lumen diameter; WT, wall thickness; LA, lumen area; WA, wall area; TA, total area.

*Multiple linear regression or logistic regression were performed to control the effect of age.

There was significant difference in clinical outcomes of asthmatics according to the distribution of adipose tissue in their body whether they were obese or not. Asthmatics without EV showed more frequent asthma exacerbation requiring use of corticosteroid or ER visit in this study. This would be explained by the presence of airway inflammation.
Because bronchial wall thickening on CT might reflect airway inflammation as mentioned above and airway inflammation is one of the most important risk factors for acute exacerbation, asthmatics without EV might be vulnerable to acute exacerbation. Only about half of the subjects in our study were BMI 25 kg/m² or higher, and it seemed that even non-obese subjects were affected by their fat location. Differences in adipocyte size and tissue biology between differing human adipose tissue depots were found in recent studies exploring human coronary inflammation. Result from that study may indicate that it is the location and composition of adipose tissue that is important in the fat associated inflammation than the total amount of fat in the body. Obesity is a well-known risk factor for asthma, and obesity related asthma subtypes had been reproducibly suggested in several unsupervised cluster analysis of asthma. However, considering that subcutaneous and visceral adipose tissues play different roles in inflammatory diseases, obesity itself would be an arbitrary phenotype rather than 'an endotype' which is a phenotypic classification that reflects the pathomechanism of the disease. Thus, separate measurement of SFA and VFA, using CT in this study, would provide a clue to better pathophysiology-based classification of asthma than just using BMI and obesity as a criterion for asthma classification. Through this study, we could suggest that not only obese patients with high BMI but also non-obese asthmatics might be affected by the adipose tissue in various ways, depending on the location of fat tissue. This might provide a clue for new endotypic approach and for personalized management for fat associated asthma.

This study has several limitations. First, we included non-severe asthmatic patients. Meticulous care is required to compare the results of this study to those of previous studies, exploring asthma using CT, which only include patients with severe asthma. Secondly, 50 asthmatic patients included in this study are too small to generalize the results. Further studies with a larger sample size will be needed to confirm our results. Thirdly, we only included airway parameters for the apical segmental bronchus in the right upper lobe due to limited use of dedicated post-processing software. However, there may be more information on airway parameters in other lobes or subsegmental bronchi. Comprehensive analysis with advanced post-processing software is necessary. Fourthly, current smokers were included in this study; while smoking induces airway inflammation, independent of asthma, excluding current smokers could bias study results as a population including smokers reflects the real population of asthmatic patients. Finally, intrathoracic fat was not evaluated in this study. We indirectly evaluated obesity using abdominal fat area only. A comprehensive method for quantifying thoracic fat is necessary to evaluate the direct association between fat and airway or lung parenchyma.

In summary, the present study suggests that the relationship between abdominal fat and asthma would vary, depending on the distribution of fat tissues. Visceral fat seems to be attributable to the bronchial luminal narrowing, while subcutaneous fat may be related to thickening of bronchial wall in asthmatic patients. Further studies are required to explore the causal relationship of fat tissue location and their effects on different endotypes of asthma.

ACKNOWLEDGMENTS

This work was supported by a clinical research grant-in-aid from the SMG-SNU Boramae Medical Center (03-2014-8).
REFERENCES

1. Dixon AE, Holguin F, Sood A, Salome CM, Pratley RE, Beuther DA, et al. An official American Thoracic Society Workshop report: obesity and asthma. Proc Am Thorac Soc 2010;7:325-35. 
   PUBMED | CROSSREF

2. Farah CS, Salome CM. Asthma and obesity: a known association but unknown mechanism. Respirology 2012;17:412-21. 
   PUBMED | CROSSREF

3. Brumpton B, Langhammer A, Romundstad P, Chen Y, Mai XM. General and abdominal obesity and incident asthma in adults: the HUNT study. Eur Respir J 2013;41:323-9. 
   PUBMED | CROSSREF

4. Gruchala-Niedoszytko M, Malgorzewicz S, Niedoszytko M, Gnacińska M, Jassem E. The influence of obesity on inflammation and clinical symptoms in asthma. Adv Med Sci 2013;58:15-21. 
   PUBMED | CROSSREF

5. Shore SA. Obesity and asthma: location, location, location. Eur Respir J 2013;41:253-4. 
   PUBMED | CROSSREF

6. Cho YS. Effective strategies for managing asthma exacerbations for precision medicine. Allergy Asthma Immunol Res 2017;9:463-5. 
   PUBMED | CROSSREF

7. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661-6. 
   PUBMED | CROSSREF

8. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007;116:1234-41. 
   PUBMED | CROSSREF

9. Kim SH, Sutherland ER, Gelfand EW. Is there a link between obesity and asthma? Allergy Asthma Immunol Res 2014;6:189-95. 
   PUBMED | CROSSREF

10. Eneli IU, Skybo T, Camargo CA Jr. Weight loss and asthma: a systematic review. Thorax 2008;63:671-6. 
    PUBMED | CROSSREF

11. Juel CT, Ali Z, Nilas L, Ulrik CS. Asthma and obesity: does weight loss improve asthma control? a systematic review. J Asthma Allergy 2012;5:21-6. 
    PUBMED | CROSSREF

12. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol 2012;85:110. 
    PUBMED | CROSSREF

13. Oh YH, Moon JH, Kim HJ, Kong MH. Visceral-to-subcutaneous fat ratio as a predictor of the multiple metabolic risk factors for subjects with normal waist circumference in Korea. Diabetes Metab Syndr Obes 2017;10:505-11. 
    PUBMED | CROSSREF

14. Gradmark AM, Rydh A, Renström F, De Lucia-Rolfe E, Sleigh A, Nordström P, et al. Computed tomography-based validation of abdominal adiposity measurements from ultrasonography, dual-energy X-ray absorptiometry and anthropometry. Br J Nutr 2010;104:582-8. 
    PUBMED | CROSSREF

15. Oh YH, Moon JH, Kim HJ, Kong MH. Visceral-to-subcutaneous fat ratio as a predictor of the multiple metabolic risk factors for subjects with normal waist circumference in Korea. Diabetes Metab Syndr Obes 2017;10:505-11. 
    PUBMED | CROSSREF

16. Hwang HJ, Hoffman EA, Lee CH, Goo JM, Levin DL, Kauczor HU, et al. The role of dual-energy computed tomography in the assessment of pulmonary function. Eur J Radiol 2017;86:320-34. 
    PUBMED | CROSSREF

17. Park SJ, Lee CH, Goo JM, Kim HJ, Park EA, Jung JW, et al. Quantitative analysis of dynamic airway changes after methacholine and salbutamol inhalation on xenon-enhanced chest CT. Eur Radiol 2012;22:2441-50. 
    PUBMED | CROSSREF

18. Chen H, Zeng QS, Zhang M, Chen RC, Xia TT, Wang W, et al. Quantitative low-dose computed tomography of the lung parenchyma and airways for the differentiation between chronic obstructive pulmonary disease and asthma patients. Respiration 2017;94:366-74. 
    PUBMED | CROSSREF
19. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.

20. Kwon HS, Lee SH, Yang MS, Lee SM, Kim SH, Kim DL, et al. Correlation between the Korean version of Asthma Control Test and health-related quality of life in adult asthmatics. J Korean Med Sci 2008;23:621-7.

21. Choi S, Hoffman EA, Wenzel SE, Castro M, Fain S, Jarjour N, et al. Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes. J Allergy Clin Immunol 2017;140:690-700.e8.

22. Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, Gern J, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012;129:S34-48.

23. Gupta S, Siddiqui S, Haldar P, Entwisle JJ, Mawby D, Wardlaw AJ, et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 2010;65:775-81.

24. Liu L, Li G, Sun Y, Li J, Tang N, Dong L. Airway wall thickness of allergic asthma caused by weed pollen or house dust mite assessed by computed tomography. Respir Med 2015;109:339-46.

25. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2013;21:E439-47.

26. Ryo M, Kishida K, Nakamura T, Yoshizumi T, Funahashi T, Shimomura I. Clinical significance of visceral adiposity assessed by computed tomography: a Japanese perspective. World J Radiol 2014;6:409-46.

27. Barton JH, Ireland A, Fitzpatrick M, Kessinger C, Camp D, Weimann R, et al. Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional study. BMC Pulm Med 2016;16:111.

28. King GG, Brown NJ, Diba C, Thorpe CW, Muñoz P, Marks GB, et al. The effects of body weight on airway calibre. Eur Respir J 2005;25:896-901.

29. Lee JH, Han KD, Jung HM, Youn YH, Lee JY, Park YG, et al. Association between obesity, abdominal obesity, and adiposity and the prevalence of atopic dermatitis in young Korean adults: the Korea National Health and Nutrition Examination Survey 2008–2010. Allergy Asthma Immunol Res 2016;8:107/4.

30. Song WJ, Kim SH, Lim S, Park YJ, Lim MH, Lee SM, et al. Association between obesity and asthma in the elderly population: potential roles of abdominal subcutaneous adiposity and sarcopenia. Ann Allergy Asthma Immunol 2012;109:245-8.

31. Conus S, Bruno A, Simon HU. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 2005;116:1228-34.

32. Grotta MB, Squebola-Cola DM, Toro AA, Ribeiro MA, Mazon SB, Ribeiro JD, et al. Obesity increases eosinophil activity in asthmatic children and adolescents. BMC Pulm Med 2013;13:39.
37. Kato H, Ueki S, Kamada R, Kihara J, Yamauchi Y, Suzuki T, et al. Leptin has a priming effect on eotaxin-induced human eosinophil chemotaxis. Int Arch Allergy Immunol 2011;155:335-44. 

38. Mclean AN, Sproule MW, Cowan MD, Thomson NC. High resolution computed tomography in asthma. Thorax 1998;53:308-14.

39. Asker S, Asker M, Ozbay B. Evaluation of airway wall thickness via high-resolution computed tomography in mild intermittent asthma. Respir Care 2014;59:550-6.

40. Gentile CL, Weir TL, Cox-York KA, Wei Y, Wang D, Reese L, et al. The role of visceral and subcutaneous adipose tissue fatty acid composition in liver pathophysiology associated with NAFLD. Adipocyte 2015;4:101-12.

41. Foster MT, Pagliassotti MJ. Metabolic alterations following visceral fat removal and expansion: beyond anatomic location. Adipocyte 2012;1:192-9.

42. Wark PA, Gibson PG. Asthma exacerbations. 3: Pathogenesis. Thorax 2006;61:909-15.

43. Antonopoulos AS, Sanna F, Sahharwal N, Thomas S, Oikonomou EK, Herdman L, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med 2017;9:eaal2658.

44. Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Psarros C, et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 2014;34:2151-9.

45. Bambace C, Sepe A, Zoico E, Teleca M, Olioso D, Venturi S, et al. Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels 2014;29:42-8.

46. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23.

47. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.

48. Kim TB, Jang AS, Kwon HS, Park JS, Chang YS, Cho SH, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J 2013;41:1308-14.

49. Gupta S, Hartley R, Khan UT, Singapuri A, Hargadon B, Monteiro W, et al. Quantitative computed tomography-derived clusters: redefining airway remodeling in asthmatic patients. J Allergy Clin Immunol 2014;133:729-738.e18.

50. Walker C, Gupta S, Hartley R, Brightling CE. Computed tomography scans in severe asthma: utility and clinical implications. Curr Opin Pulm Med 2012;18:42-7.